Please assess the completion status of the following clinical trial:

Trial Title: Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, postmenopausal women who seek treatment for hot flashes~* Patients using hormone replacement therapy(HRT) must be willing to discontinue treatment~* Patients must be experiencing moderate to severe hot flashes~* Patients must be able to sign the informed consent~* Patients must be able to enter simple commands and complete questionnaires on the frequency and severity of their hot flashes using an electronic diary~Other inclusions apply.~Exclusion Criteria:~* Patients with hypersensitivity to Gabapentin~* Patients with severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss~* Patients treated with estrogen pellets or injectable progestin drug therapy within 6 months.~* Patients currently treated with Gabapentin or Pregabalin for any indication, including vasomotor symptoms~Other exclusions apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Gabapentin Extended Release (Type: EXPERIMENTAL): Active treatment
- Placebo (Type: OTHER): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).